BUZZ-Valeant Pharmaceuticals: Estimates strong Q3 results

Wed Sep 24, 2014 10:20am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drugmaker's shares up about 5.4 pct at C$135.15

** Company's U.S.-listed shares up about 5 percent at $121.71

** Says it estimates Q3 revenue above Street expectations

** Says expects overall Q3 same-store organic growth to be more than 15 pct

** Says adjusted profit to come in above its own forecast

** Up to Tuesday's close of C$128.29, company's Toronto-listed shares had fallen nearly 8 percent since April 21, when Valeant teamed up with activist-investor William Ackman to buy botox-maker Allergan Inc